Related Experiment Videos
Preclinical pharmacology of alendronate
G A Rodan1, J G Seedor, R Balena
1Merck Research Laboratories, West Point, Pennsylvania 19486.
Abstract:
This brief review summarizes some of the preclinical findings of studies aimed at assessing the efficacy and safety of the aminobisphosphonate alendronate (ALN) in preventing or restoring the bone loss caused by calcium or estrogen deficiency. Mode of action studies show that ALN localizes at sites of bone resorption and inhibits osteoclastic activity. In secondary hyperparathyroidism caused by calcium-deficient diets in the rat, ALN reduced the bone loss. For low doses, daily administration proved most efficient. In ovariectomized rats, ALN both prevented and reversed the bone changes produced by estrogen deficiency at oral doses equivalent to 0.1 mg/kg per day or higher, and also maintained the mechanical strength of vertebrae. In ovariectomized baboons, which show bone changes similar to those seen in ovariectomized women, ALN also prevented the increase in bone turnover and increased both bone volume and bone strength in vertebrae. In a comparative study between ALN and etidronate, we found that ALN was 1000-fold more potent in inhibiting bone resorption and had at least a 1000-fold higher safety margin with respect to inhibition of mineralization and osteomalacia.
Insights
Alendronate (ALN) effectively prevents and reverses bone loss from calcium or estrogen deficiency in preclinical models. This aminobisphosphonate inhibits osteoclast activity, showing superior potency and safety compared to etidronate.
Area of Science:
- Pharmacology
- Bone Biology
- Preclinical Research
Background:
- Bone loss is a significant health concern, often linked to calcium or estrogen deficiencies.
- Osteoporosis and secondary hyperparathyroidism contribute to increased fracture risk.
- Aminobisphosphonates are a class of drugs investigated for bone loss treatment.
Purpose of the Study:
- To review preclinical findings on the efficacy and safety of alendronate (ALN).
- To assess ALN's potential in preventing or restoring bone loss due to calcium or estrogen deficiency.
- To understand ALN's mechanism of action in bone resorption.
Main Methods:
- Preclinical studies in rats and baboons were reviewed.
- Alendronate's effect on bone loss in models of secondary hyperparathyroidism and estrogen deficiency was evaluated.
- Comparative analysis with etidronate was performed to determine potency and safety margins.
Main Results:
- Alendronate (ALN) localized to bone resorption sites and inhibited osteoclastic activity.
- ALN reduced bone loss in rats with secondary hyperparathyroidism, with daily administration being most effective at low doses.
- In ovariectomized rats and baboons, ALN prevented and reversed bone loss, maintained vertebral strength, and reduced bone turnover.
- ALN demonstrated 1000-fold greater potency and safety margin than etidronate.
Conclusions:
- Alendronate (ALN) is a highly effective aminobisphosphonate for preventing and restoring bone loss in preclinical models.
- ALN's mechanism involves inhibiting osteoclastic activity and improving bone structural integrity.
- ALN exhibits superior efficacy and safety compared to etidronate, suggesting significant therapeutic potential.